Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans
- Simone RBM Eussen^{1, 2},
- Cathy JM Rompelberg^{2}Email author,
- Olaf H Klungel^{1} and
- Jan CH van Eijkeren^{2}
DOI: 10.1186/1476-511X-10-187
© Eussen et al; licensee BioMed Central Ltd. 2011
Received: 31 August 2011
Accepted: 21 October 2011
Published: 21 October 2011
Abstract
Background
To examine the effects on LDL cholesterol of the combined use of statins and phytosterols/-stanols, in vivo studies and clinical trials are necessary. However, for a better interpretation of the experimental data as well as to possibly predict cholesterol levels given a certain dosing regimen of statins and phytosterols/-stanols a more theoretically based approach is helpful. This study aims to construct a mathematical model to simulate reductions in low-density lipoprotein (LDL) cholesterol in persons who combine the use of statins with a high intake of phytosterols/-stanols, e.g. by the use of functional foods.
Methods and Results
The proposed model includes the cholesterol pool size in the liver and serum levels of very low-density lipoprotein (VLDL) cholesterol. Both an additional and a multiplicative effect of phytosterol/-stanol intake on LDL cholesterol reduction were predicted from the model. The additional effect relates to the decrease of dietary cholesterol uptake reduction, the multiplicative effect relates to the decrease in enterohepatic recycling efficiency, causing increased cholesterol elimination through bile. From the model, it was demonstrated that a daily intake of 2 g phytosterols/-stanols reduces LDL cholesterol level by about 8% to 9% on top of the reduction resulting from statin use. The additional decrease in LDL cholesterol caused by phytosterol/-stanol use at the recommended level of 2 g/d appeared to be similar or even greater than the decrease achieved by doubling the statin dose.
Conclusion
We proposed a simplified mathematical model to simulate the reduction in LDL cholesterol after separate and combined intake of statins and functional foods acting on intestinal (re)absorption of cholesterol or bile acids in humans. In future work, this model can be extended to include more complex (regulatory) mechanisms.
Keywords
model statins phytosterols phytostanols LDL cholesterol lipids coronary heart diseaseBackground
Increased total cholesterol and low-density lipoprotein (LDL) cholesterol levels represent a major risk for atherosclerosis and coronary heart disease (CHD). Lipid-lowering drugs, of which the hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have shown to be the most effective, reduce morbidity and mortality in patients with CHD [1–3]. Since the last decade of the 20^{th} century, more interest has been given to changing dietary habits, for example with the appearance of the so-called functional foods. Dairy products enriched with phytosterols/-stanols are one of the best known and most used functional foods to lower elevated total and LDL cholesterol levels. Phytosterols/-stanols are thought to compete with cholesterol for solubilisation into mixed micelles, the transport vehicles for cholesterol across the intestinal wall. Consequently, the intestinal (re)absorption of cholesterol is reduced, faecal output is increased and total and LDL cholesterol levels are lowered by 6% and 10%, respectively [4, 5]. Due to the rising public awareness of health and nutritional improvement, and the mounting evidence of the effectiveness of phytosterols/-stanols, it is conceivable that in the near future an increasing number of people will combine their statin therapy with these functional foods.
To examine the effects on total and LDL cholesterol levels of the combined intake of statins and phytosterols/-stanols, in vivo studies and clinical trials are necessary. However, for a better interpretation of the experimental data as well as to possibly predict cholesterol levels given a certain dosing regimen of statins and phytosterols/-stanols a more theoretically based approach is helpful.
The present study focuses on the combined effect of atorvastatin and phytosterols/-stanols. However, our model can easily be applied to other statins and similar acting functional foods (e.g. soluble dietary fibres) as well. Moreover, based on certain genetic variants associated with cholesterol absorption and production an individual's specific reduction in total and LDL cholesterol can be predicted.
Methods
Model variables and abbreviations used in the study
Model variable | Abbreviation |
---|---|
Endogenously produced cholesterol | P _{ C } |
Dietary cholesterol intake | I _{ C } |
External daily statin dose | S |
External daily free phytosterol/-stanol dose | PS |
(Steady state) concentration of free cholesterol in the liver | C |
VLDL particles | V |
Absorbed cholesterol fraction | f _{ abs } |
Fraction of produced VLDL cholesterol that re-enters the liver | f _{ back } |
Association rate of VLDL particles and free cholesterol to VLDL cholesterol | k _{ VC } |
Excretion of cholesterol from the cholesterol pool by bile | k _{ bile } |
Excretion of cholesterol through the formation of bile salts | k _{ salts } |
Reduction in cholesterol pool size | R _{ C } |
Cholesterol pool concentration in absence of statins and phytosterols/-stanols | C _{0} |
Endogenous produced cholesterol in absence of statins and phytosterols/-stanols | P _{C,0} |
Uptake of dietary cholesterol in absence of statins and phytosterols/-stanols | U _{C,0} |
Absorbed cholesterol fraction in absence of statins and phytosterols/-stanols | f_{ abs },_{0} |
Reduction in endogenous cholesterol production | R _{ P } |
Reduction in fraction of cholesterol uptake from the diet | R _{ U } |
Ratio of exponential rates of different cholesterol elimination routes | ρ _{ k } |
VLDL cholesterol production rate | P _{ VC } |
Transformation rate of VLDL cholesterol to LDL cholesterol | k _{ VL } |
(Steady state) VLDL cholesterol concentration | VC |
Maximum rate of change in (V)LDL cholesterol due to saturated uptake process | V _{ max } |
Michaelis-Menten constant in (V)LDL cholesterol model | K _{ M } |
(Steady state) LDL cholesterol concentration | LC |
LDL cholesterol production from VLDL cholesterol | P _{ LC } |
Clearance rate of LDL cholesterol through non-saturated process | k _{ n } |
Maximal achievable reduction in endogenous cholesterol production | R _{ P, max } |
Half maximum reduction statin dose | S _{P, 1/2} |
Maximal achievable reduction in fraction of cholesterol uptake from the diet | R _{ U, max } |
Half maximum reduction phytosterol/-stanol dose | PS _{U, 1/2} |
Basic cholesterol model
Modelling of the cholesterol pool
A mass balance is considered with cholesterol input from endogenously produced cholesterol P_{ C } and from cholesterol taken up from the diet, I_{ C } . Only a fraction f_{ abs } of dietary cholesterol is assumed to be taken up across the gut wall, and consequently the uptake of dietary cholesterol is U_{ C } = f_{ abs }·I_{ C } . The mass balance output consists of produced VLDL cholesterol, cholesterol cleared by elimination of excess cholesterol through bile and cholesterol needed to produce bile salts. For simplicity, we neglect the reverse cholesterol transport mediated by high-density lipoprotein (HDL) and the existence of a hepatic cholesteryl ester pool that might be involved in cholesterol homeostasis. Moreover, up- and down-regulation of LDL receptors is not considered.
The model considers only steady state levels of cholesterol, VLDL cholesterol and LDL cholesterol. For a steady cholesterol level, the input of cholesterol should be balanced by its output. Clearance of cholesterol by VLDL cholesterol formation, bile excretion and bile salts formation is assumed to be non-saturated and is described by the product of clearance rates and steady cholesterol level.
Of the daily amount of VLDL cholesterol formation, k_{ VC }V ·C, the product of steady cholesterol level C with VLDL particles V and association rate k_{ VC } , a fraction f_{ back } is reabsorbed into the liver. It consists of VLDL cholesterol that is not used for LDL cholesterol production and of LDL cholesterol. The other fraction 1- f_{ back } is taken up by the extrahepatic tissues, of which part is excreted through HDL cholesterol, which will not be considered in this modelling approach. As a consequence of this recycling, the effective clearance rate of cholesterol to VLDL cholesterol is (1- f_{ back } )·k_{ VC }V. The amount of cholesterol eliminated through bile salts formation is k_{ salt }·C.
Likewise, because it is assumed that not only dietary cholesterol but also cholesterol cleared by bile with a daily amount of k_{ bile }·C is reabsorbed through enterohepatic recycling, the effective clearance rate of cholesterol through bile is (1- f_{ abs } )·k_{ bile } .
As we consider the effect of statins and phytosterols/-stanols on LDL cholesterol levels, the model becomes slightly more complicated. First, it is assumed that reduced cholesterol production P_{ C } is related to the external daily dose S of statins, P_{ C } = P_{ C } (S). Second, it is assumed that the reduced cholesterol fraction absorbed from dietary cholesterol intake relates to the amount of intake of phytosterols/-stanols (PS), f_{ abs } = f_{ abs } (PS).
It should be noted that it is implicitly assumed that there is no interaction between statins and phytosterols/-stanols consumed, i.e. both compounds work simultaneously, independent of each other.
Modelling of VLDL cholesterol level
In the modelling of the cholesterol pool (equation (1)) it is assumed that the production of VLDL cholesterol P_{ VC } is proportional to both the concentration of VLDL particles and the free cholesterol level: P_{ VC } = k_{ VC }V ·C(S, PS). Like for cholesterol, a steady state level V C(S, PS) of VLDL cholesterol follows from the balance between its production and its clearance. VLDL cholesterol is assumed to be cleared due to the production of LDL cholesterol with daily clearance of k_{ VL }·V C(S, PS) and due to saturated receptor-mediated uptake from blood into the liver and extrahepatic tissues [6]. Receptor-mediated uptake is assumed to follow Michaelis-Menten kinetics with a maximum clearance rate V_{ max } and a saturation constant K_{ M } .
The steady state VLDL cholesterol level can be obtained by solving the implicit equation for V C(S, PS). The explicit expression for VC is deduced in Appendix 1. Note that of the Michaelis-Menten saturated clearance of VLDL cholesterol from blood a fraction f_{ back } goes into the liver. The complementary fraction 1- f_{ back } goes into extrahepatic tissues (Figure 1).
Modelling of LDL cholesterol level
from which the LDL cholesterol level can be obtained by solving the implicit equation (3) for LC(S, PS). The explicit expression for LC can be found in Appendix 1. Similar as for VLDL cholesterol, a fraction f_{ back } of the Michaelis-Menten saturated clearance of LDL cholesterol from blood goes into the liver. The complementary fraction 1- f_{ back } goes into extrahepatic tissues (Figure 1). V_{ max }, K_{ M } are the same maximum elimination rate and saturation constant of the Michaelis-Menten saturated uptake of VLDL cholesterol from blood into the liver. These constants are assumed to be the same, but this assumption is not essential.
Cholesterol reduction model
Modelling cholesterol reduction by statins and phytosterols/-stanols
Here, like for cholesterol production and absorption, C_{0} and U_{C, 0}denote, respectively, the cholesterol pool concentration and dietary uptake in absence of statins and phytosterols/-stanols. In the first factor at the right side, the ratio ρ_{ k } denotes the proportion of cholesterol elimination through VLDL cholesterol production and bile salts production to cholesterol elimination through bile excretion, as introduced in Appendix 2.
The following remarks should be made regarding this model. First, the effectiveness of statins or phytosterols/-stanols to lower cholesterol production is determined by the ratio of the contribution of endogenous produced cholesterol and the contribution of dietary cholesterol uptake to the cholesterol pool. Thus, when dietary cholesterol uptake is increased, the effectiveness of statins (first term in the second factor) is reduced with respect to the effectiveness of phytosterols/-stanols. Obviously, the opposite holds true for the effectiveness of phytosterols/-stanols.
Second, the reduction in the absorbed fraction of cholesterol has an additional effect in total cholesterol pool reduction (the second term in the second factor at the right side of equation (4)) and a multiplicative one (first factor at the right side of equation (4)). The additional effect relates to the decrease of dietary cholesterol uptake reduction, whereas the multiplicative effect relates to the decrease in enterohepatic recycling efficiency, causing increased cholesterol elimination through bile.
Third, the additional reduction caused by statin and phystosterol/-stanol use is a weighted sum of the reduction in cholesterol production and cholesterol absorption because 1/(1+ P_{C, 0}/U_{C, 0}) +1/(1+ U_{C, 0}/P_{C, 0}) = 1.
Formulating reduction as a Michaelis-Menten process
where R_{ P, max }≤ 1 determines the maximum achievable reduction and S_{P, 1/2}is the half maximum reduction statin dose.
where R_{ U, max }≤ 1 determines the maximum achievable reduction and PS_{U, 1/2}is the half maximum reduction phytosterol/-stanol dose.
In this derivation we used 1/(1+ U_{C, 0}/P_{C, 0})+ 1/(1+ P_{C, 0}/U_{C, 0}) = 1
Parameter value estimation
The reduced steady state cholesterol concentration can be obtained from a given daily dose of statins or phytosterols/-stanols by applying the reduction model proposed in equation (7). From that reduced concentration, the reduced steady VLDL cholesterol level can be derived by solving equation (2), and subsequently the reduced LDL cholesterol level can be derived by solving equation (3). However, to be applicable in practice, model parameters should be known. In this section all parameters of our model are quantified based on data in the literature.
Basic cholesterol model parameters
It is assumed that the liver produces P_{C, 0}= 1000 mg cholesterol per day [9–12]. Furthermore, we assumed a dietary cholesterol intake of I_{ C } = 400 mg/d, of which a fraction of 50% (f_{abs, 0}= 0.5)[9, 13] is taken up in the liver (U_{C, 0}= 200 mg/d). The same fraction is supposed to be recycled through enterohepatic recycling of cholesterol excreted with bile. The final contribution to liver cholesterol input is assumed to be 70% of produced VLDL cholesterol (f_{ back } = 0.7) [14].
It is assumed that the amount of cholesterol excreted with bile is 1000 mg/d[9, 13, 15] and consequently, 500 mg/d re-enters the liver. The rate of excretion through the formation of bile salts is 400 mg/d [16]. Concerning the local liver balance, the input is 1000 (produced cholesterol, P_{C ,0}) plus 200 (uptake, U_{C, 0}) plus 500 (recycled, (1- f_{abs, 0})·k_{ bile }·C_{0}) plus 700 (back transport, f_{ back }·k_{ VC }V·C_{0}) making a total of 2400 mg/d. The output is 1000 (bile, k_{ bile }·C_{0}) plus 400 (bile salts, k_{ salts }·C_{0}), and making a total of 2400 mg/d, plus the production of 1000 mg VLDL cholesterol per day (VLDL cholesterol, k_{ VC }V·C_{0}). Moreover, as the elimination from the liver is proportional to the production rates of bile salts, cholesterol in bile and VLDL cholesterol, the ratio of these production rates is k_{ salts } : k_{ bile } : k_{ VC }V = 0.4: 1: 1.
From Sahlin et al. [17, 18] we estimated the free cholesterol content in liver to be 55 nmol/mg microsomal protein. Together with a microsomal protein content of 45 mg/g liver[19] this amounts to 2500 μmol/kg liver which equals 960 mg free cholesterol/kg liver. From this free cholesterol concentration and the daily bile excretion, one can derive k_{ bile } = 1000/960 = 1.04, k_{ VC }V = 1.04 and k_{ salts } = 0.416.
Dietschy et al. [6] report LDL cholesterol model parameter values in humans. When assuming a subject of 70 kg, these values are V_{ max } = 1340 mg/d, K_{ M } = 90 mg/dl, k_{ n } = 5 dl/d and P_{ LC } = 910 mg/d. Based on these values, a steady cholesterol level LC = 67 mg/dl results from equation (3).
The VLDL:LDL:HDL cholesterol ratio was estimated to be 1:8:3 [20]. Thus the corresponding VLDL level is 8.4 mg/dl. As the LDL cholesterol production rate is equal to k_{ VL }·VC (equation (3)), k_{ VL } = 108 (dl/d). From equation (2) a VLDL cholesterol production of 1020 mg/d can be calculated. Above it is assumed to be 1000 mg/d which shows a consistency error of 2% only.
Cholesterol reduction model parameters
From the ratio between the effective clearances, introduced in the basic cholesterol model parameters section, one can derive that the ratio ρ_{ k } in equation (4) is 0.7. The four remaining parameters R_{ P, max } , S_{P, 1/2}, R_{ U, max } , PS_{U, 1/2}are unknown and were fitted to optimise their likelihood in comparing modelled LDL cholesterol reduction induced by cholesterol reduction to LDL cholesterol reduction data. Thus, given an estimation of the four cholesterol reduction model parameters, the reduction in steady state cholesterol is calculated, the resulting reduction in VLDL cholesterol is determined from equation (2) and the resulting reduction in LDL cholesterol is determined from equation (3).
To simulate the appropriateness of our model, reduced levels are compared with the experimental data for separate intakes of atorvastatin[21] and phytosterols/-stanols [22]. For this procedure we use for R_{ P, max } , S_{P, 1/2}data from a recent meta-analysis of Berry et al. [21] that shows experimentally determined in vivo LDL cholesterol reduction due to atorvastatin dose. For R_{ U, max } , PS_{U, 1/2}we use data presented in Demonty et al. [22] showing experimentally determined in vivo LDL cholesterol reduction due to intake of free phytosterols/-stanols, i.e. phytosterols/-stanols not in esterified form. Finally, we simulate reductions after combined intake of atorvastatin and phytosterols/-stanols.
Results
Separate intake
LDL cholesterol reduction by atorvastatin
We applied equation (7) together with the corresponding VLDL and LDL cholesterol levels equations (2) and (3) to data in Berry et al. [21] in a LDL cholesterol reduction model using the model parameters given above. The unknown parameter values in equation (7) were estimated through fitting the maximum reduction R_{ P, max } and the statin dose S_{P, 1/2}when half maximum reduction is reached.
LDL cholesterol reduction by phytosterols/-stanols
We applied equation (7) together with the corresponding VLDL and LDL cholesterol levels equations (2) and (3) to data in Demonty et al. [22] in a LDL cholesterol reduction model. The unknown parameter values in equation (7) were estimated through fitting the maximum reduction R_{ U, max }and the free phytosterol/-stanol dose PS_{U, 1/2}when half maximum reduction is reached.
Combined intake
LDL cholesterol reduction by combined use of atorvastatin and phytosterols/-stanols
The reduction in enterohepatic recycling contributes for 68%, 58%, 56% and 55% of the total decrease in LDL cholesterol levels at daily statin doses of 0, 20, 40 and 80 mg, respectively. At the same recommended phytosterol/-stanol intake level of 2 g/d, the additional decrease in LDL cholesterol by physterols/-stanols for a daily statin dose of 20 mg (4.8%) is equal to the additional decrease by doubling daily statin dose to 40 mg (5.3%). For a daily statin dose of 40 mg the additional decrease in LDL cholesterol by physterols/-stanols (4.5%) is 30% larger than the additional decrease by doubling daily statin dose to 80 mg (3.2%).
Discussion
In this paper, a mathematical model is presented that simulates the reductions in LDL cholesterol after separate and combined intake of atorvastatin and phytosterols/-stanols in humans. We demonstrated that a daily intake of 2 g phytosterols/-stanols reduces LDL cholesterol level by about 8% to 9% on top of the reduction resulting from statin use. This level of reduction is consistent with the findings of randomised controlled trials [23–28]. The additional decrease in LDL cholesterol caused by phytosterol/-stanol use at the recommended level of 2 g/d appeared to be similar or even greater than the decrease achieved by doubling the statin dose, a finding that has been observed previously in human trials [23, 29]. The reduction in LDL cholesterol level due to phytosterol/-stanol use results from a decrease in the intestinal uptake of dietary cholesterol (additional effect) and a reduction in enterohepatic recycling (multiplicative effect). For daily statin doses of 20 mg or more, the contribution of the enterohepatic recycling reduction is 55% or more. When no statin is used, this contribution is 68%.
Mathematical models provide a valuable means of interpreting experimental data and improving the ability to predict the response to a given treatment. Other modelling studies have focused on cholesterol metabolism, but are merely aimed at answering questions on the cellular level or tend to focus on specific areas of cholesterol metabolism, such as the fluid dynamics of lipid accumulation on the arterial wall or the chemical kinetics of LDL oxidation [30–32].
In the present study, the separate and combined effects of the cholesterol-lowering drug atorvastatin and functional foods with phytosterols/-stanols in humans were modelled. Yet, this model can easily be applied to other statins and similar acting (functional) foods as well. Products with soluble dietary fibres, for example, are also known to lower total and LDL cholesterol by reducing the intestinal (re)absorption of cholesterol and bile acids, although they work by a different mechanism as phytosterols/-stanols [4, 33, 34]. Moreover, individuals' specific reductions in total and LDL cholesterol can be predicted, based on certain genetic variants. For example, the ratio of cholesterol synthesis to cholesterol absorption varies between individuals and is an important determinant for the cholesterol pool size [35]. Also mutations in the LDL receptor gene causing familial hypercholesterolaemia can be modelled by varying the parameter V_{ max } .
There are a few possible directions for improving our model. First, the model could be extended by including the up- and down regulatory mechanisms involving the LDL receptors. Nonetheless, since we assumed that the clearing of (V)LDL cholesterol from the blood follows Michaelis-Menten kinetics, we implicitly included receptor-mediated uptake in the model. Also other regulatory control pathways were disregarded, such as the existence of a hepatic cholesteryl ester pool that might be involved in cholesterol homeostasis and the regulatory loop in the synthesis of LDL receptors [30]. Another extension would include reverse cholesterol transport mediated by HDL [20]. Moreover, the proposed model assumes that the reducing effects of statins and functional foods are independent of each other. Although this is likely the case for the combination of phytosterols/-stanols and statins,[22, 24, 36, 37] it is uncertain whether this applies for other food-drug combinations. It has, for example, been proposed that soluble dietary fibres reduce the intestinal uptake of statins [38, 39]. Our model should be extended to include such an interaction.
In conclusion, we proposed a simplified mathematical model to simulate the reduction in LDL cholesterol after separate and combined intake of statins and functional foods acting on intestinal (re)absorption of cholesterol or bile acids in humans. In future work, this model can be extended to include more complex (regulatory) mechanisms.
Appendix 1
Steady VLDL cholesterol concentration
Here, we suppress the dependencies on statin administration S and dietary phytosterol/-stanol intake PS.
Steady LDL cholesterol concentration
Appendix 2
Reduction in steady state cholesterol
In the third line, the ratio of clearance rates ρ_{ k } = ((1-f_{ back } )·k_{ VC }V + k_{ salts } )/k_{ bile } is introduced. In this line also one instance of f_{abs, 0}·I_{ C } is substituted by U_{C, 0}. In the fourth line the definition of production reduction and, after dividing out intake I_{ C } , of uptake reduction is substituted.
Declarations
Acknowledgements
The authors thank Jeljer Hoekstra for detailed and helpful comments on earlier drafts of this manuscript.
Authors’ Affiliations
References
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344 (8934): 1383-1389.Google Scholar
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005, 366 (9493): 1267-78.View ArticlePubMedGoogle Scholar
- Amarenco P, Labreuche J, Lavalle P, Touboul P: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004, 35 (12): 2902-2909. 10.1161/01.STR.0000147965.52712.fa 10.1161/01.STR.0000147965.52712.faView ArticlePubMedGoogle Scholar
- Plat J, Mensink RP: Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol. 2005, 96 (1A): 15D-22D.View ArticlePubMedGoogle Scholar
- Marinangeli CP, Varady KA, Jones PJ: Plant sterols combined with exercise for the treatment of hypercholesterolemia: overview of independent and synergistic mechanisms of action. J Nutr Biochem. 2006, 17 (4): 217-24. 10.1016/j.jnutbio.2005.09.003 10.1016/j.jnutbio.2005.09.003View ArticlePubMedGoogle Scholar
- Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993, 34 (10): 1637-59.PubMedGoogle Scholar
- Shum YY, Huang N, Walter G, Black A, Sekerke C, Chang T, Whitfield LR: Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther Drug Monit. 1998, 20 (1): 41-49. 10.1097/00007691-199802000-00008 10.1097/00007691-199802000-00008View ArticlePubMedGoogle Scholar
- Davis H, Altmann S: Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta. 2009, 1791 (7): 679-683. 10.1016/j.bbalip.2009.01.002 10.1016/j.bbalip.2009.01.002View ArticlePubMedGoogle Scholar
- McNamara DJ: Effects of fat-modified diets on cholesterol and lipoprotein metabolism. Annu Rev Nutr. 1987, 7: 273-290. 10.1146/annurev.nu.07.070187.001421 10.1146/annurev.nu.07.070187.001421View ArticlePubMedGoogle Scholar
- Rajaratnam RA, Gylling H, Miettinen TA: Cholesterol absorption, synthesis, and fecal output in postmenopausal women with and without coronary artery disease. Arterioscler Thromb Vasc Biol. 2001, 21 (10): 1650-1655. 10.1161/hq1001.097019 10.1161/hq1001.097019View ArticlePubMedGoogle Scholar
- Insel P, Ross D, McMahon K, Bernstein M, : Nutrition. 2011, Jones and Bartlett Publishers, Sudbury, MA,Google Scholar
- Stipanuk MH, : Biochemical and physiological aspects of human nutrition. Lipid metabolism-Synthesis and oxidation. 2000, W.B. Saunders Co., Philadelphia, USA,Google Scholar
- van der Velde A, Brufau G, Groen A: Transintestinal cholesterol efflux. Curr Opin Lipidol. 2010, 21 (3): 167-171. 10.1097/MOL.0b013e3283395e45 10.1097/MOL.0b013e3283395e45View ArticlePubMedGoogle Scholar
- Demirezen EM, Barlas Y: A simulation model for blood cholesterol dynamics and related disorders. 2009, 2011 (12 July): 1-38.Google Scholar
- Phillips GB: The lipid composition of human bile. Biochim Biophys Acta. 1960, 41: 361-363. 10.1016/0006-3002(60)90026-3 10.1016/0006-3002(60)90026-3View ArticlePubMedGoogle Scholar
- Bisschop P, Bandsma RHJ, Stellaard F, Harmsel A, Meijer A, Sauerwein H, Kuipers F, Romijn J: Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am J Clin Nutr. 2004, 79 (4): 570-576.PubMedGoogle Scholar
- Sahlin S, Granstrm L, Gustafsson U, Sthlberg D, Backman L, Einarsson K: Hepatic esterification rate of cholesterol and biliary lipids in human obesity. J Lipid Res. 1994, 35 (3): 484-490.PubMedGoogle Scholar
- Sahlin S, Sthlberg D, Einarsson K: Cholesterol metabolism in liver and gallbladder mucosa of patients with cholesterolosis. Hepatology. 1995, 21 (5): 1269-1275.PubMedGoogle Scholar
- Houston JB: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994, 47 (9): 1469-1479. 10.1016/0006-2952(94)90520-7 10.1016/0006-2952(94)90520-7View ArticlePubMedGoogle Scholar
- Kumar PJ, Clark ML: Clinical medicine - Diabetes Mellitus and other disorders of metabolism. W.B. Saunders. 2002,Google Scholar
- Berry DA, Berry SM, McKellar J, Pearson TA: Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am Heart J. 2003, 145 (6): 1036-1045. 10.1016/S0002-8703(03)00106-6 10.1016/S0002-8703(03)00106-6View ArticlePubMedGoogle Scholar
- Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, Geleijnse JM, Trautwein EA: Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr. 2009, 139 (2): 271-84.View ArticlePubMedGoogle Scholar
- Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol. 2000, 86 (1): 46-52. 10.1016/S0002-9149(00)00976-0 10.1016/S0002-9149(00)00976-0View ArticlePubMedGoogle Scholar
- Simons LA: Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol. 2002, 90 (7): 737-40. 10.1016/S0002-9149(02)02600-0 10.1016/S0002-9149(02)02600-0View ArticlePubMedGoogle Scholar
- Richter WO: Treatment of severe hypercholesterolemia with a combination of beta-sitosterol and lovastatin. Curr Ther Res. 1996, 57 (7): 497-505. 10.1016/S0011-393X(96)80059-2. 497,. 10.1016/S0011-393X(96)80059-2View ArticleGoogle Scholar
- Castro Cabezas M, de Vries JH, Van Oostrom AJ, Iestra J, van Staveren WA: Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. J Am Diet Assoc. 2006, 106 (10): 1564-9. 10.1016/j.jada.2006.07.009 10.1016/j.jada.2006.07.009View ArticlePubMedGoogle Scholar
- Goldberg AC, E OR, Bateman JH, Schimmoeller L, McPherson TB, Spilburg CA: Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol. 2006, 97 (3): 376-9. 10.1016/j.amjcard.2005.08.056 10.1016/j.amjcard.2005.08.056View ArticlePubMedGoogle Scholar
- De Jong A, Plat J, Bast A, Godschalk RW, Basu S, Mensink RP: Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. Eur J Clin Nutr. 2008, 62: 263-73. 10.1038/sj.ejcn.1602733 10.1038/sj.ejcn.1602733View ArticlePubMedGoogle Scholar
- Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003, 78 (8): 965-78. 10.4065/78.8.965 10.4065/78.8.965View ArticlePubMedGoogle Scholar
- August E, Parker KH, Barahona M: A dynamical model of lipoprotein metabolism. Bull Math Biol. 2007, 69 (4): 1233-1254. 10.1007/s11538-006-9132-6 10.1007/s11538-006-9132-6View ArticlePubMedGoogle Scholar
- Chun PW, Espinosa AJ, Lee CW, Shireman RB, Brumbaugh EE: Low density lipoprotein receptor regulation. Kinetic models. Biophys Chem. 1985, 21 (3-4): 185-209. 10.1016/0301-4622(85)80005-3 10.1016/0301-4622(85)80005-3View ArticlePubMedGoogle Scholar
- Wattis JAD, O'Malley B, Blackburn H, Pickersgill L, Panovska J, Byrne HM, Jackson KG: Mathematical model for low density lipoprotein (LDL) endocytosis by hepatocytes. Bull Math Biol. 2008, 70 (8): 2303-2333. 10.1007/s11538-008-9347-9 10.1007/s11538-008-9347-9PubMed CentralView ArticlePubMedGoogle Scholar
- Theuwissen E, Mensink RP: Water-soluble dietary fibers and cardiovascular disease. Physiol Behav. 2008, 94 (2): 285-92. 10.1016/j.physbeh.2008.01.001 10.1016/j.physbeh.2008.01.001View ArticlePubMedGoogle Scholar
- Eussen S, Klungel O, Garssen J, Verhagen H, van Kranen H, van Loveren H, Rompelberg C: Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. Br J Nutr. 2010, 103 (9): 1260-1277. 10.1017/S0007114509993230 10.1017/S0007114509993230View ArticlePubMedGoogle Scholar
- Gylling H, Miettinen TA: Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients. Atherosclerosis. 2002, 160 (2): 477-81. 10.1016/S0021-9150(01)00608-6 10.1016/S0021-9150(01)00608-6View ArticlePubMedGoogle Scholar
- Eussen S, de Jong N, Rompelberg C, Garssen J, Verschuren W, Klungel O: Dose-dependent cholesterol-lowering effects of phytosterol/phytostanol-enriched margarine in statin users and statin non-users under free-living conditions. Public Health Nutr. 2011, 1-10.Google Scholar
- de Jong N, Zuur A, Wolfs MC, Wendel-Vos GC, van Raaij JM, Schuit AJ: Exposure and effectiveness of phytosterol/-stanol-enriched margarines. Eur J Clin Nutr. 2007, 61: 1407-15. 10.1038/sj.ejcn.1602660 10.1038/sj.ejcn.1602660View ArticlePubMedGoogle Scholar
- Richter WO, Jacob BG, Schwandt P: Interaction between fibre and lovastatin. Lancet. 1991, 338 (8768): 706-View ArticlePubMedGoogle Scholar
- Eussen SRBM, Rompelberg CJM, Andersson K, Klungel O, Hellstrand P, Oste R, van Kranen H, Garssen J: Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice. Pharmacological research. 2011, 64 (1): 36-43. 10.1016/j.phrs.2011.02.008 10.1016/j.phrs.2011.02.008View ArticlePubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.